No committee data
Expert AnalysisPro
/ 100 Political Alpha
Upgrade to see committee overlap, performance context, and full expert analysis.
Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
UpgradeLive
Track congressional trades for SPCXSPCX congressional trades
2 matched disclosures
Tracked disclosures
2
Lawmakers
2
Buy / sell
2 / 0
Avg post-trade move
N/A
Latest filing 2026-07-02
SPCX congressional trades snapshot
This page summarizes public STOCK Act disclosures involving SPCX. It is useful for seeing which lawmakers reported SPCX transactions, how many filings are visible, the buy/sell mix, and whether the newest public filing describes a recent or delayed trade.
Last updated
Jul 2, 2026
Data source
Public House and Senate STOCK Act disclosures normalized by Congressional Trader.
Key caveat
Filing date can trail transaction date. This page is for research and monitoring, not investment advice.
What the SPCX congressional trade page shows
Congressional Trader tracks 2 public STOCK Act disclosures for SPCXacross 2 lawmakers. This page separates purchases from sales, shows filing delays, and links each disclosure back to the individual politician profile when available.
The most recent SPCX filing shown here was filed on Jul 2, 2026 by Gilbert Ray Cisneros as a purchase. Related lawmakers include Daniel Meuser, Gilbert Ray Cisneros.
Top lawmakers for SPCX
Pro performance summary
Unlock 30/90-day post-trade summaries, committee overlap, and CSV-oriented research views for high-intent ticker research.
Compare Pro plansNo committee data
Expert AnalysisPro
/ 100 Political Alpha
Upgrade to see committee overlap, performance context, and full expert analysis.
Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
UpgradeFAQ
Which lawmakers traded SPCX?
Recent SPCX disclosures include Daniel Meuser, Gilbert Ray Cisneros.
What is the buy/sell mix for SPCX?
The visible sample currently shows 2 purchases and 0 sales or partial sales.
Should I trade based on SPCX disclosures?
No. This page summarizes public filings for research and monitoring. It is not investment advice.